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A B S T R A C T   
Background: In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) 
which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant 
was estimated to have a transmission fitness advantage of around 40–80 % (Volz et al., 2021; Leung et al., 2021; 
Davies et al., 2021). 
Aim: This study aims to estimate the transmission fitness advantage and the effective reproductive number of 
B.1.1.7 through time based on data from Switzerland. 
Methods: We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland 
between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the 
B.1.1.7 variant and quantify the variant’s transmission fitness advantage on a national and a regional scale. 
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Results: We estimate B.1.1.7 had a transmission fitness advantage of 43–52 % compared to the other variants 
circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number 
above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. 
Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07–1.41] from 01 January until 17 
January 2021 and 1.18 [1.06–1.30] from 18 January until 01 March 2021 based on the whole genome 
sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive 
number was 1.14 [1.00–1.26] based on all confirmed cases. For reference, Switzerland applied more non- 
pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 
01 March 2021. 
Conclusion: The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected 
based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated 
doubling time of around 2–3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.   
1. Introduction 
In mid-December 2020 a SARS-CoV-2 variant named B.1.1.7 was 
first reported as more transmissible than previously circulating strains 
(Rambaut et al., 2020a; NERVTAG, 2021; Public Health England, 2021). 
This variant, whose name comes from the pangolin lineage nomencla-
ture (Rambaut et al., 2020b) and which was first identified in the UK, 
carries the N501Y mutation in the spike protein which may increase 
ACE2 receptor affinity (Starr et al., 2020). Within only a few months, 
B.1.1.7 became the dominant variant in the UK epidemic. 
Based on these first reports, Switzerland began an intense effort to 
detect and trace B.1.1.7 (Goncalves Cabecinhas et al., 2021). The first 
infections with B.1.1.7 in Switzerland were confirmed on 24 December 
2020 and retrospective analyses identified B.1.1.7 in samples dating 
back to October (Goncalves Cabecinhas et al., 2021). In total, 1370 in-
fections with B.1.1.7 were confirmed up to 05 February 2021 (Goncalves 
Cabecinhas et al., 2021). 
Observing a variant increase in frequency does not necessarily mean 
it has a transmission fitness advantage. For example, a variant named 
20A.EU1 spread rapidly across Europe in summer 2020. However, data 
suggests that extended travel and superspreading events caused that 
spread, not a viral transmission fitness advantage (Hodcroft et al., 
2020). Alternatively, partial immune escape may help a variant spread 
compared to other variants. 
In the case of B.1.1.7, Davies et al. (2021) concluded that the vari-
ant’s spread is poorly explained by a hypothesis of immune escape. 
Instead, B.1.1.7’s rapid increase in frequency in many high-prevalence 
regions across the UK in parallel is well-explained by a transmission 
fitness advantage (Davies et al., 2021). Indeed, several different analyses 
based on UK data suggest B.1.1.7 has a transmission fitness advantage 
between 40 and 80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 
2021). Davies et al. (2021) also obtain similar estimates based on data 
from Denmark. Finally, analysis of the spread of the N501Y mutation in 
Switzerland suggests a similar transmission fitness advantage (Trans-
mission of SARS-CoV, 2021). 
In this study, we determine the frequency of B.1.1.7 through time in 
Switzerland and calculate its transmission fitness advantage based on 
three different datasets. First, we generated whole-genome sequences 
from randomly selected samples provided by the diagnostics company 
Viollier AG. Second, we use data from the diagnostics company Dr Risch 
AG which screens all their samples for B.1.1.7. 
Finally, we use whole-genome sequences generated from all patients 
who tested positive for SARSCoV-2 at the University Hospital Geneva 
(HUG) with CT values below 32 beginning 23 December 2020. These 
three datasets are differently representative of Switzerland at the na-
tional and regional levels. Based on these data, we quantified the 
transmission fitness advantage of B.1.1.7 for Switzerland as well as for 
the seven Swiss economic regions (Grossregionen). We additionally 
calculated the reproductive number for B.1.1.7 and show how the 
number of B.1.1.7 infections developed through time. 
The core plots presented here were regularly updated between mid- 
January and mid-April 2021 on SARS-CoV (2021a) and, since then are 
available on the CoV-Spectrum website (CoV-Spectrum, 2021). Some of 
the results are additionally displayed on the Swiss National COVID-19 
Science Task Force website as of May 2021 (SARS-CoV, 2021b). The 
code and data used for this study are publicly available on Github 
(Github et al., 2021). All sequences are available on GISAID (Elbe and 
Buckland-Merrett, 2017) (section A.7). 
2. Methods 
2.1. Data 
We analyze three different datasets. The primary dataset is a set of 
whole-genome sequences generated from samples provided by Viollier 
AG, a large Swiss diagnostics company that processes SARS-CoV2 sam-
ples from across Switzerland. Each week, a random selection of samples 
from amongst all positive tests processed by the company were selected 
for whole-genome sequencing. Each sample is associated with a test date 
and the canton in which the test was performed. Whole-genome se-
quences were generated from selected samples according to the pro-
cedures described in the supplementary materials section A.1. We define 
a sequence to be a B.1.1.7 sample if at least 80 % of the lineagedefining, 
non-synonymous nucleotide changes according to Rambaut et al. 
(2020a) are present. 
The second dataset is daily counts of B.1.1.7 infections amongst tests 
processed by Dr Risch AG, another Swiss diagnostics company. Each 
count is associated with a test date but not a geographic location. The 
screening procedures for B.1.1.7 used to generate these data are 
described in the supplementary materials section A.2. 
The third and final dataset is a set of whole-genome sequences 
generated from patients at the University Hospital Geneva (HUG). 
Samples from all patients who tested positive there with a CT of below 
32 were sent for whole-genome sequencing, which were generated ac-
cording to the procedures described in the supplementary materials 
section A.1. As with the first dataset, a sequence is defined to be a B.1.1.7 
sample if at least 80 % of the lineage-defining, non-synonymous 
nucleotide changes are present. 
These three datasets differ in their size and geographic representa-
tion. The first dataset includes 9772 sequences from the study period 14 
December 2020 to 11 March 2021 (approximately 780 per week, status 
current as of 23 March 2021). These data represent 5.3 % of the 184,165 
confirmed infections in Switzerland during this period. The second 
dataset includes 12,019 samples screened for B.1.1.7. Taken together, 
these two datasets represent 11.8 % of all confirmed SARS-CoV-2 in-
fections in Switzerland during our study period. Finally, the third 
dataset is specific to the Lake Geneva region. It covers most of the study 
period, from 23 December 2020 to 04 March 2021, and includes 2074 
sequences which represent 7% of all confirmed infections in the Lake 
Geneva region during that period. 
Regarding geographic location, the diagnostic companies Viollier AG 
and Dr Risch AG both processes samples from all over Switzerland but 
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the intensity varies across regions. The set of sequenced samples inherits 
this uneven geographical distribution. For example, relative to the total 
number of confirmed infections, the Viollier AG dataset includes over 
eight times more sequenced infections from the region Nordwestschweiz 
than from the region Ticino (Table S1). The Dr Risch AG data, on the 
other hand, has much better coverage of Eastern Switzerland (Table S2). 
In summary, these two national-level datasets differ in their geographic 
biases. 
In what follows, we analyze the frequency of identified B.1.1.7 
samples per day in the three datasets and compare our results between 
them. Both national-level datasets (Viollier AG and Dr Risch AG) are 
used to generate estimates on the national level, and comparing between 
them shows the effect of different geographic biases. Since only the 
Viollier AG dataset is resolved at the regional level, all regional-level 
estimates are based on this dataset. Finally, the HUG dataset specific 
to the Lake Geneva region allows a more detailed view on B.1.1.7 spread 
in this region and a validation of results generated using the other two 
datasets. 
2.2. Statistical inference 
We fit a logistic model to the frequency of B.1.1.7 samples per day to 
estimate the logistic growth rate a and the sigmoid’s midpoint t0. From 
that, we derive an estimate of the transmission fitness advantage of 
B.1.1.7 under a continuous (fc) and a discrete (fd) model. Each model 
could plausibly describe the actual dynamics, so we present results from 
both for comparison. Further, we estimate the reproductive number R 
for the B.1.1.7 and non-B.1.1.7 infections. The mathematical derivations 
are described in the supplementary materials in the sections A.3 and A.4. 
Finally, we show the projected number of confirmed infections in the 
future under the continuous model. We initialize the model on 01 
January 2021 with the estimated number of B.1.1.7 and non-B.1.1.7 
confirmed infections on that day. We assume a reproductive number 
for the non-B.1.1.7 infections as estimated on the national level for 01 
January-17 January 2021. Further, we assume that the expected gen-
eration time is 4.8 days and the fitness advantage is the estimated fc for 
the region and dataset of interest (Table 1). 
3. Results 
We estimate the logistic growth rate a and the sigmoid’s midpoint t0 
based on the two nationallevel datasets from Viollier AG and Dr Risch 
AG (Table 1). Taking the estimates of both datasets together, we obtain a 
growth rate a of 0.07− 0.09 per day for Switzerland. For each economic 
region, the estimated uncertainty interval of a overlaps with the Swiss- 
wide uncertainty. We have little data for two out of seven regions 
(Ticino and Central Switzerland; <1100 sequences in total) resulting in 
very wide uncertainty intervals. From the t0 estimates, we observe that 
the Lake Geneva region was about 2 weeks ahead of the rest of 
Switzerland with respect to B.1.1.7 spread. This confirms estimates from 
Transmission of SARS-CoV (2021). Our initial analyses of the data in 
January 2021 projected that B.1.1.7 will become dominant in 
Switzerland in March 2021. Indeed, our latest data points suggest a 
frequency of B.1.1.7 in confirmed infections of around 80 % for 11 
March 2021. 
In Figs. 1 and 2, we graphically illustrate the logistic growth in fre-
quency of B.1.1.7 and show the daily data together with an estimate of 
the proportion of B.1.1.7 under the logistic growth model. 
As a validation of the logistic growth parameter estimates, we 
additionally analyzed the third, Lake Geneva-specific dataset from HUG. 
The estimates for the Lake Geneva region based on Viollier AG data 
agree very well with these independent estimates based on HUG data 
(Table 1 and Fig. S2). 
Next, we estimate the reproductive number for B.1.1.7 and non- 
B.1.1.7 infections on a national scale (Fig. 3). We note that non- 
pharmaceutical interventions to combat SARS-CoV-2 spread in 
Switzerland were strengthened on 18 January 2021 and then relaxed 
on 01 March 2021. Between 01 January and 17 January 2021, the 
reproductive number for B.1.1.7 was significantly above 1 (Viollier AG 
dataset: 1.24 [1.07–1.41], Dr Risch AG dataset: 1.46 [1.21–1.72]) while 
the reproductive number of non-B.1.1.7 was below 1 (Viollier AG 
dataset: 0.83 [0.65–1.00], Dr Risch AG dataset: 0.81 [0.67− 0.96]). 
The reproductive number for B.1.1.7 calculated based on the Viollier 
AG dataset did not drastically change after 18 January 2021 (1.18 
[1.06–1.30]) and agrees well with the estimates based on the Dr Risch 
AG dataset (1.15 [1.01,1.29]). The non-B.1.1.7 reproductive number 
also did not drastically change after this timepoint (Viollier AG dataset: 
0.80 [0.68− 0.91], Dr Risch AG dataset: 0.85 [0.76,0.93]). 
As expected from assuming a constant B.1.1.7 transmission fitness 
advantage, the ratio of the reproductive numbers for B.1.1.7 and non- 
B.1.1.7 based on the Viollier AG dataset was roughly constant 
throughout January and February. However, based on the Dr Risch AG 
dataset, the ratio of the reproductive numbers for B.1.1.7 and non- 
B.1.1.7 unexpectedly dropped in January. We suspect a potential bias 
in this dataset (such as preferential inclusion of B.1.1.7 in early January) 
because all estimates for B.1.1.7 in early January agree except those 
based on the Dr Risch AG dataset. 
Our data does not allow us to estimate the variant-specific repro-
ductive number for March yet. However, for the time period 10 March- 
16 March 2021, we can estimate the reproductive number based on all 
confirmed infections (Real-time estimates, 2021) (1.14 [1.00–1.26]). 
Since this estimate is based on confirmed cases from the second part of 
March when we project around 90–95 % of all confirmed infections are 
B.1.1.7, this estimate should only slightly underestimate the reproduc-
tive number of B.1.1.7. In summary, we estimate the reproductive 
number for B.1.1.7 was above 1 since January 2021 while the repro-
ductive number for non-B.1.1.7 variants was below 1. 
Table 1 
Estimates of the growth rate a and the sigmoid’s midpoint t0 (measured in days 
after Dec. 14)as well as the transmission fitness advantages fd and fc are reported. 
In the fc calculation, the Swiss-wide estimate of the reproductive number for the 
time period 01 January 2021-17 January 2021 is assumed for the Rc. mismatch 
of the total number of infections and the Viollier AG-based projections.  
Region Dataset a t0 fd = exp 
(ag) − 1 
fc = ag/Rc 
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Next, we calculate the transmission fitness advantage fc of B.1.1.7 
under our continuous-time model using the average reproductive 
number estimated between 01 January 2021− 17 January 2021. 
Further, we calculate the transmission fitness advantage fd under a 
discrete-time model. In both cases, we assume a generation time g of 4.8 
days (the same as the mean generation time used to estimate the 
reproductive number). Table 1 shows the estimated fitness values under 
both methods. On a national level, we estimate a fitness advantage of 
43–52 % across methods and datasets. The regional estimates overlap 
with this interval. We note that we use the national reproductive number 
for the regional fc estimates. Since Ticino had a lower reproductive 
number averaged over all variants (Real-time estimates, 2021), the fc for 
Ticino may be an underestimate. Similarly, the Lake Geneva region had 
a higher reproductive number so the fc for Lake Geneva may be an 
overestimate. 
Finally, we show the projected dynamics of the epidemic under the 
continuous model using parameter values based on epidemic conditions 
in the first half of January (Figs. 4 and 5). We show how the number of 
B.1.1.7 infections develops over time in blue and how the number of 
non-B.1.1.7 infections develops in green. In particular, in January 2021, 
the model projects a decline in overall infections due to a decline in non- 
B.1.1.7 variants. However, the number of B.1.1.7 variants increases. 
Under this model, the total number of infections will increase again 
once B.1.1.7 becomes dominant. It is important to note that this simple 
model is intended to highlight whether epidemic dynamics change 
compared to early January 2021 due to B.1.1.7, and thus it assumes the 
transmission dynamics are constant. In particular, the model does not 
include effects of non-pharmaceutical interventions introduced on 18 
January 2021 or removed on 01 March 2021, vaccination, immunity 
after infection, and population heterogeneity. 
In our projections, we assume that dynamics remained unchanged 
since early January. In order to explore to what extend this assumption 
Fig. 1. Logistic growth of frequency of B.1.1.7 
in Switzerland. Green points are the empirical 
proportions of B.1.1.7 for each day (i.e. number 
of B.1.1.7 samples divided by the total number 
of samples). Blue vertical lines are the esti-
mated 95 % uncertainty of this proportion for 
each day, assuming a simple binomial sampling 
and Wilson uncertainty intervals. A logistic 
growth function fit to the data from all of 
Switzerland is shown in black with the 95 % 
uncertainty interval of the proportions in gray 
(i.e. p(t) from Eqn. 2 and 5 in the supplemen-
tary material section A.3).   
Fig. 2. Logistic growth of frequency of B.1.1.7 in the seven economic regions of Switzerland. For details see legend of Fig. 1.  
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Fig. 3. Estimates of the effective reproductive number R of the B.1.1.7 variant and non-B.1.1.7 variants. Results in the top row are based on Viollier data, and in the 
bottom row based on Risch data. Within each panel, the top row shows the results of the continuously varying R estimation, and the bottom of the piecewise constant 
R estimation. The left column shows the R estimates, whereas the right shows the ratio between R estimated for B.1.1.7 and R estimated for all nonB.1.1.7 variants. 
The confidence intervals for the R of non-B117 variants show a 7-day periodicity due to lower case reporting on weekends. The R value was allowed to change on 18 
January 2021 in the statistical inference as measures were tightened on that day. 
Fig. 4. Change in the number of B.1.1.7 vari-
ants and in the number of all cases through time 
for Switzerland. Based on the average repro-
ductive number Rc for Switzerland estimated 
for the time period 01 January 2021-17 
January 2021 (i.e. prior to the tightening of 
measures on 18 January 2021) and the trans-
mission fitness advantage fc for the same time 
period, we plot the expected number of B.1.1.7 
variants (blue) and the expected number of 
non-B.1.1.7 variants (green) under the contin-
uous model. The model is initialized on Jan. 1 
with the total number of cases and the esti-
mated number of B.1.1.7 cases on that day. This 
model is compared to data: The dark green line 
is the total number of confirmed cases (7-day 
average). The dark blue line is the estimated 
number of confirmed B.1.1.7 cases (7-day average); this number is the product of the total number of confirmed cases for a day by the proportion of the B.1.1.7 
variant for that day. If the empirical data develops as the model, the dark blue line follows the upper end of the blue area and the dark green line follows the upper 
end of the green area.   
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is violated, we investigate whether empirical infection numbers follow 
the model-based projections. In Figs. 4 and 5, we show that the model 
(solid areas) and empirical data (lines) follow the same trajectories 
throughout January 2021 across datasets and regions, with the excep-
tion of the Ticino and Lake Geneva regions. As discussed above, we 
believe these discrepancies are a result of regional differences in the 
reproductive number (see also the supplementary materials, section 
A.5). After January 2021, we notice a discrepancy between the empir-
ical data and the projections at the national level based on the Viollier 
AG dataset (Fig. 4) as well as the five regions with a good match in 
January (Fig. 5, also based on the Viollier AG dataset). The empirical 
data are below the model projections. This discrepancy is consistent 
with a slight reduction in the reproductive number after 18 January 
2021. 
On the other hand, the empirical data follow model projections using 
parameters estimated from the Dr Risch AG dataset very well until 
March (Fig. 4). Thus, changing the model from the Viollier AG-based 
parameters (R-value 0.83, fitness advantage 0.48) to the Dr Risch AG- 
based parameters (R-value 0.81, fitness advantage 0.45) leads to a 
very good fit until mid-March, highlighting that in a phase of overall 
exponential growth, slight changes of the parameters can have large 
consequences on the total number of infections. In other words, a slight 
reduction of transmission in late January 2021 and/or a slight mis-
specification of the Viollier AG-based parameters can explain the recent 
parameters can explain the recent mismatch of the total number of in-
fections and the Viollier AG-based projections. 
4. Discussion 
We quantified the Swiss-wide transmission fitness advantage and the 
effective reproductive number of B.1.1.7 based on two national-level 
datasets. One dataset also allows us to obtain estimates specific to the 
seven Swiss economic regions. Swiss-wide estimates point towards a 
transmission fitness advantage of 43–52 %. Based on our early 
sequencing data, we already projected in January 2021 that B.1.1.7 will 
become dominant in March. The same conclusion was reached by 
Transmission of SARS-CoV (2021) in January 2021 based on Swiss data 
tracking S:501Y mutations. Indeed, on 11 March 2021 around 80 % of 
characterized infections carried the B.1.1.7 variant. As of the date of 
writing, 26 March 2021, we expect almost all new infections may be 
caused by B.1.1.7 since cases are confirmed 8–11 days after the time of 
infection in Switzerland. Thus, the Swiss epidemic is now a B.1.1.7 
epidemic. 
The increase in the frequency of B.1.1.7 in Switzerland occurred as 
expected given the variant’s large transmission advantage. Unless 
measures such as contact tracing particularly target B.1.1.7, the vari-
ant’s transmission advantage causes it to dominate. However, the speed 
at which a variant increases in absolute numbers is a function of vari-
ables such as non-pharmaceutical interventions, adherence to such 
measures, and levels of immunity in the population. 
We show that in the first half of January 2021, the absolute numbers 
of B.1.1.7 infections increased (R-value 1.24 [1.07–1.41] for 01 
January-17 January2021 based on our Swiss-wide sequence dataset 
from Viollier AG) while the absolute numbers of all other infections 
decreased (R-value 0.83 [0.651.00]). For the second half of January 
2021, the reproductive number for B.1.1.7 and non-B.1.1.7 infections 
only decreased slightly according to the Viollier AG data. 
To facilitate a comparison of the B.1.1.7 reproductive number before 
and after the introduction of more non-pharmaceutical interventions on 
18 January 2021, we note that the doubling time for a reproductive 
Fig. 5. Change in the number of B.1.1.7 variants and in the number of all cases through time for the seven Swiss economic regions. For details see legend of Fig. 4. 
We use the reproductive number estimated for the whole of Switzerland for the continuous-time model such that we can compare to what extend regions differ from 
the national dynamic. The regional transmission fitness advantage is taken from Table 1. 
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number of 1.24 is 15 days compared to 20 days for a reproductive 
number of 1.18, which makes a substantial difference in the overall 
epidemic dynamics. 
Estimates based on the Swiss-wide Dr Risch AG data agree very well 
with this pattern, with the exception of B.1.1.7 in early January where a 
higher reproductive number is estimated. We speculate that the large 
drop in the reproductive number for B.1.1.7 based on the Dr Risch AG 
data is due to a bias in the early B.1.1.7 data, which possibly contained 
samples preferentially stemming from B.1.1.7 infections. 
We estimate the reproductive number averaged over all confirmed 
infections in Switzerland from 10 March to 16 March 2121 (among 
which B.1.1.7 is projected to have caused 90–95 % of infections) was 
1.14 [1.00–1.26]. Taken together, these reproductive number estimates 
highlight that B.1.1.7 spread exponentially in Switzerland beginning in 
early January 2021. Our point estimate for the doubling time is around 
2–3.5 weeks. 
When comparing confirmed infections to model-based projections, 
we observe that the number of confirmed infections is lower in February 
2021 than expected based on the model fit to Viollier AG data and using 
parameter estimates from the first half of January 2021. This may reflect 
a small overall slow-down in transmission, which is also suggested by 
our reproductive number estimates. However, this slow-down was not 
large and the reproductive number estimates are quite uncertain. On the 
other hand, the number of confirmed infections agrees very well with 
the model fit to Dr Risch AG data. We suggest that either a slight slow- 
down in transmission in late January and/or a slight misspecification of 
the Viollier AG-based model parameters may explain the discrepancy 
(assumed parameters are: non-B.1.1.7 reproductive number of 0.83 vs 
0.81 and B.1.1.7 transmission fitness advantage of 0.48 vs 0.45 from 
Viollier AG and Dr Risch AG data, respectively). In summary, the 
reduction seen in the Viollier AG data may be the outcome of the 
strengthening of non-pharmaceutical interventions on 18 January or a 
slight bias in the parameter estimates from early January 2021. The 11.5 
% of confirmed infections characterized in our dataset is not sufficient to 
quantify the change in dynamics precisely enough to evaluate the effect 
of these measures on the reproductive number. 
Our data reveal that the seven different economic regions of 
Switzerland were sampled with different intensities. For this reason, we 
expect it is more reasonable to assume a homogeneous sampling in-
tensity at the regional level than at the national level. On the other hand, 
infections imported from other regions likely represent a larger fraction 
of regional infections than imports from abroad do for national in-
fections. However, the economic regions represent well-defined regions 
where we expect a lot of mixing within and less mixing across regions. 
Thus, we also performed analyses specific to the seven economic re-
gions. Our regional estimates for B.1.1.7 transmission fitness advantage 
are largely in line with the national estimates, though of course with 
larger uncertainty. Two of the regions (Ticino, Central Switzerland) 
have too little data to make precise statements. Geneva is estimated to be 
around 2 weeks ahead in the B.1.1.7 dynamics compared to Switzerland 
as a whole. One explanation may be the large number of UK travelers to 
ski resorts in the Valais in December 2020. 
Overall, we see a consistent signal for a large transmission advantage 
of B.1.1.7 in Switzerland across datasets and regions. Our results 
confirm other estimates from studies from the UK (Volz et al., 2021; 
Leung et al., 2021; Davies et al., 2021), Denmark (Davies et al., 2021), 
and Switzerland (Transmission of SARS-CoV, 2021); looking at 501Y 
mutations). Furthermore, the strengthening of non-pharmaceutical in-
terventions in Switzerland on 18 January 2021 could not stop the spread 
of B.1.1.7. We estimate that B.1.1.7 spread exponentially from its arrival 
in Switzerland in late 2020 until the end of our study period. Thus, 
despite the additional control efforts, total infections began growing 
exponentially again once B.1.1.7 became dominant in March 2021. Our 
core plots are available on SARS-CoV (2021a) and SARS-CoV (2021b) 
for real-time monitoring. Further, our model is integrated in the 
CoV-Spectrum website where it can be applied to other countries and 
variants (CoV-Spectrum, 2021). 
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